Acceleron to Webcast Overview of ACE-083 Phase 2 Trial

Acceleron LogoAn archive of the webcast can be accessed on the Company's website.

Acceleron Pharma Inc. will host an educational webinar on FSHD and the Company's Phase 2 clinical trial of ACE-083 in FSHD patients. The webinar will be led by neuromuscular disease expert, Jeffrey Statland, M.D., M.P.H., and Acceleron management, at 10:00 a.m. EDT on Friday, October 28, 2016.

Dr. Statland is an assistant professor of neurology at the University of Kansas Medical Center with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD, one of the most prevalent forms of muscular dystrophy, characterized by a progressive loss of muscle strength. During the webinar, Dr. Statland will provide an overview of FSHD, its clinical manifestations and unmet medical need. Acceleron management will provide an overview of ACE-083 and the design of the upcoming Phase 2 clinical trial. At the end of the presentation, Dr. Statland and Acceleron management will be available to answer questions from the call participants.

Conference Call and Webcast Details

Date: Friday, October 28, 2016

Time: 10:00 a.m. (EDT)

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron FSHD Call.

About ACE-083

ACE-083 is a therapeutic candidate that acts as a ligand trap for members in the transforming growth factor-beta (TGF-β) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases in which improved muscle strength in a specific set of muscles may provide a clinical benefit, such as facioscapulohumeral muscular dystrophy.